Good news for chronic and accelerated stage CML patients resistant to or intolerant of imatinib and who live in the South West........ let's hope that NICE will follow suit and give a positive decision for guidance for in all other regions of England. (Wales and Scotland give their own guidance)
'The Peninsula Health Technology Commissioning Group (PHTCG) has come to a decision on the use of dasatinib and nilotinib in the management of chronic myeloid leukaemia.
Where clinically appropriate these drugs may be used for patients who are resistant to standard first line therapy with imatinib who are in either the chronic or accelerated phase of the disease.
They may also be used for patients in these phases who cannot tolerate imatinib.'
See full PDF under newswire.
Sandy
